Astatine-211--Tellurium Radiocolloid Cures Experimental Malignant Ascites

An investigation of the efficacy of astatine-211—tellurium colloid for the treatment of experimental malignant ascites in mice reveals that this α-emitting radiocolloid can be curative without causing undue toxicity to normal tissue. By comparison, negatron-emitting phosphorus-32 as colloidal chromi...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 1981-04, Vol.212 (4492), p.340-341
Main Authors: Bloomer, William D., McLaughlin, William H., Neirinckx, Rudi D., Adelstein, S. James, Gordon, Phillip R., Ruth, Thomas J., Wolf, Alfred P.
Format: Article
Language:English
Subjects:
Alpha Particles
Animals
Antineoplastics
Ascites
Ascites - radiotherapy
Astatine
Astatine - therapeutic use
Cell Survival - radiation effects
Chromium - therapeutic use
Chromium Compounds
Colloids
Female
Liver
Medical treatment
Mice
Neoplasm Transplantation
Neoplasms, Experimental - radiotherapy
Ovarian Neoplasms
Pathology
Phosphates - therapeutic use
Phosphorus Radioisotopes - therapeutic use
Radioisotopes - therapeutic use
Radiotherapy
Tellurium
Tellurium - therapeutic use
Transplantation, Homologous
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An investigation of the efficacy of astatine-211—tellurium colloid for the treatment of experimental malignant ascites in mice reveals that this α-emitting radiocolloid can be curative without causing undue toxicity to normal tissue. By comparison, negatron-emitting phosphorus-32 as colloidal chromic phosphate had no antineoplastic activity. The most compelling explanation for this striking difference is the dense ionization and short range of action associated with α-emission. These results have important implications for the development and use of α -emitters as radiocolloid therapy for the treatment of human tumors.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.7209534